Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of Δ9-tetrahydrocannabinol in rats

Brain Research

Volumn 839, Issue 1, 1999, Pages 173-179

  Manzanares, Jorge ^a,b   Corchero, Javier ^a,b   Fuentes, José A ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO PLURIDISCIPLINAR   (Spain)

Author keywords

9 Tetrahydrocannabinol; ACTH; Corticosterone hypothalamus; Naloxone; Pituitary; SR 141716A

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; CORTICOSTERONE; CORTICOTROPIN; DRONABINOL; NALOXONE; OPIATE; OPIATE RECEPTOR; RIMONABANT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ADRENOCORTICOTROPIC HORMONE; ANALYSIS OF VARIANCE; ANIMALS; CORTICOSTERONE; INJECTIONS, INTRAVENTRICULAR; MALE; NALOXONE; NARCOTIC ANTAGONISTS; PIPERIDINES; PITUITARY-ADRENAL SYSTEM; PSYCHOTROPIC DRUGS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; RECEPTORS, OPIOID; TETRAHYDROCANNABINOL;

EID: 0033592210     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01756-4     Document Type: Article

References (31)

1. Armario A., Castellanos J.M. A simple procedure for direct corticosterone radioimmunoassay in the rat. Rev. Esp. Fisiol. 40:1984;437-441.
2. Arts C.J., Koppeschaar H.P., Veeman W., Thijssen J.H. A direct radioimmunoassay for the determination of adrenocorticotropic hormone (ACTH) and a clinical evaluation. Ann. Clin. Biochem. 22:1985;247-256.
3. 9-Tetrahydrocannabinol increases prodynorphin and preproenkephalin gene expression in the spinal cord of the rat. Life Sci. 61:1997;PL39-PL43.
4. 9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. Eur. J. Pharmacol. 323:1999;193-195.
5. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
6. Dewey W.L. Cannabinoid pharmacology. Pharmacol. Rev. 38:1986;151-178.
7. Haracz J.L., Bloom A.S., Wang R.I.H., Tseng L.F. Effect of intraventricular β-endorphin and morphine on hypothalamic-pituitary-adrenal activity and the release of pituitary β-endorphin. Neuroendocrinology. 33:1981;170-175.
8. Hayes A.G., Stewart B.R. Effect of μ and κ opioid receptor agonists on rat plasma corticosterone levels. Eur. J. Pharmacol. 116:1985;75-79.
9. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
10. Iyengar S., Kim H.S., Wood P.L. Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat. J. Pharmacol. Exp. Ther. 238:1986;429-436.
11. Iyengar S., Kim H.S., Wood P.L. μ, δ, κ and ε-Opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: subchronic tolerance studies of endogenous opioid peptides. Brain Res. 435:1987;220-226.
12. Jackson A.L., Murphy L.L. Role of the hypothalamic-pituitary-adrenal axis in the suppression of luteinizing hormone release by delta-9-tetrahydrocannabinol. Neuroendocrinology. 65:1997;446-452.
13. J.F.R. König, R.A. Klippel, The Rat Brain: a Stereotaxic Atlas of the Forebrain and Lowers Parts of the Brain Stem, Williams and Wilkins, Baltimore, 1963.
14. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., Fuentes J.A. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Mol. Brain Res. 55:1998;126-132.
15. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., Fuentes J.A. Pharmacological and biochemical interactions between opiates and cannabinoids. Trends Pharmacol. Sci. 20:1999;287-294.
16. Martin-Calderon J.L., Munoz R.M., Villanua M.A., del Arco I., Moreno J.L., Rodriguez de Fonseca F., Navarro M. Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur. J. Pharmacol. 344:1998;77-86.
17. Patel N.A., Moldow R.L., Patel J.A., Wu G., Chang S.L. Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain. Brain Res. 797:1998;225-233.
18. Pechnick R.N. Effects of opioids on the hypothalamo-pituitary-adrenal axis. Annu. Rev. Pharmacol. Toxicol. 32:1993;353-382.
19. Puder M., Weidenfeld J., Chowers I., Nir I., Conforti N., Siegel R.A. Corticotrophin and corticosterone secretion following delta 1-tetrahydrocannabinol, in intact and in hypothalamic deafferentated male rats. Exp. Brain Res. 46:1982;85-88.
20. Pugh G. Jr., Mason D.J. Jr., Combs V., Welch S.P. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP 55,940 in the spinal cord. J. Pharmacol. Exp. Ther. 281:1997;730-737.
21. 9-tetrahydrocannabinol induced analgesia by morphine in mice, Eur. Involvement of μ and opioid receptors. Eur. J. Pharmacol. 318:1996;11-16.
22. 9tetrahydrocannabinol induced analgesia in mice. Eur. J. Pharmacol. 301:1996;75-81.
23. 9-tetrahydrocannabinol-induced antinociception in mice. Neuropharmacology. 37:1998;215-222.
24. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara O., Soubrie P., Brelire J.C., Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
25. 37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther. 276:1996;56-64.
26. Rodriguez de Fonseca F., Villanua M.A., Munoz R.M., San-Martin-Clark O., Navarro M. Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats. Neuroendocrinology. 61:1995;714-721.
27. Rubio P., Rodriguez de Fonseca F., Munoz R.M., Ariznavarreta C., Martin-Calderon J.L., Navarro M. Long-term behavioral effects of perinatal exposure to delta 9-tetrahydrocannabinol in rats: possible role of pituitary-adrenal axis. Life Sci. 56:1995;2169-2176.
28. Vela G., Ruiz-Gayo M., Fuentes J.A. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology. 34:1995;665-668.
29. Weidenfeld J., Feldman S., Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology. 59:1994;110-112.
30. Welch S.P. Blockade of cannabinoid induced antinociception by norbinaltorphimine, but not N,N-diallyltyrosineAibPhenylalanineleucine, ICI 174,864 or naloxone in mice. J. Pharmacol. Exp. Ther. 265:1993;633-640.
31. Wenger T., Jamali K.A., Juaneda C., Leonardelli J., Tramu G. Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Biochem. Biophys. Res. Commun. 237:1997;724-728.